AbbVie's Strategic Bet: The $10.9 Billion Acquisition of Apogee Therapeutics
AbbVie is set to acquire Apogee Therapeutics for $10.9 billion, signaling a strategic move in the immunology sector.
BMO Capital Upgrades Incyte: A Sign of Renewed Confidence
BMO Capital's upgrade of Incyte (INCY) signals confidence in the company's strategic direction and potential investor opportunities.
Prime Medicine's PM359 Lands FDA RMAT Designation: What It Means for Gene Therapy
Prime Medicine ($PRME) secures FDA RMAT status for PM359 in CGD treatment, signaling accelerated development path and potential market valid…
REGENXBIO’s FDA Alignment: A Positive Step for NAVSUNLI Gene Therapy
REGENXBIO's alignment with the FDA on NAVSUNLI could influence investor sentiment and future share performance.
AbbVie’s Strategic Move: $10.9 Billion Acquisition of Apogee Therapeutics
AbbVie’s acquisition of Apogee Therapeutics highlights strategic shifts amidst revenue pressures.
Incyte Corporation Receives Upgrade: What This Means for INCY Investors
BMO Capital upgrades Incyte Corporation to Market Perform, signaling potential stock price momentum for investors.
REGENXBIO's Path to FDA Approval: A Key Milestone for NAVSUNLI
REGENXBIO aligns with the FDA for NAVSUNLI resubmission, a crucial step for investors to monitor.
AbbVie Set to Expand Inflammatory Disease Portfolio with $10.9 Billion Acquisition of Apogee Therapeutics
AbbVie is on the verge of a significant $10.9 billion acquisition of Apogee Therapeutics, enhancing its position in inflammatory disease tre…
GSK's Utebzi Approved: A Milestone in Antibiotic Treatment
GSK's Utebzi gains FDA approval, marking a pivotal moment in the fight against antibiotic resistance.
Moderna's Flu Vaccine Receives FDA Panel Approval: A New Opportunity for MRNA
Moderna's flu vaccine approval could reshape its market strategy and revenue, particularly for adults aged 50 and older.
Elicio Therapeutics Suffers Major Setback After Phase II Trial Results
Elicio Therapeutics faces a significant challenge as its Phase II trial results disappoint, impacting investor confidence and market positio…
Spero Therapeutics Soars Following FDA Approval of Utebzi
Spero Therapeutics shares jumped 16% after FDA approval of Utebzi, signaling strong market confidence and growth potential.